Metagenomi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	30.91	52.3	44.76	17.2	0.24
Revenue Growth (YoY)	-43.88%	16.84%	160.21%	6978.19%	-
Cost of Revenue	96.1	109.18	94.4	43.14	14.48
Gross Profit	-65.18	-56.88	-49.65	-25.94	-14.24
Selling, General & Admin	27.09	32.02	28.85	18.7	9.71
Operating Expenses	27.09	32.02	28.85	18.7	9.71
Operating Income	-92.27	-88.9	-78.49	-44.64	-23.95
Interest Expense	-	-	-	-0.1	-0.3
Interest & Investment Income	10.78	14.72	15.47	3.42	0.04
Other Non Operating Income (Expenses)	-0.13	-0.21	-0.07	0.2	0
EBT Excluding Unusual Items	-81.62	-74.39	-63.1	-41.12	-24.2
Gain (Loss) on Sale of Investments	-8.42	-9.19	2.87	0.09	2.76
Pretax Income	-90.04	-83.57	-60.23	-41.02	-21.44
Income Tax Expense	-1.3	-5.51	8.03	2.57	-
Net Income	-88.74	-78.06	-68.26	-43.59	-21.44
Net Income to Common	-88.74	-78.06	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	37	33	3	3	6
Shares Outstanding (Diluted)	37	33	3	3	6
Shares Change (YoY)	51.55%	870.10%	0.15%	-40.27%	-
EPS (Basic)	-2.38	-2.36	-20.05	-12.82	-3.77
EPS (Diluted)	-2.38	-2.36	-20.05	-12.82	-3.77
Free Cash Flow	-92.45	-112.19	-101.22	15.75	21.35
Free Cash Flow Per Share	-2.48	-3.40	-29.73	4.63	3.75
Gross Margin	-210.86%	-108.78%	-110.93%	-150.81%	-
Operating Margin	-298.48%	-170.00%	-175.38%	-259.53%	-9854.73%
Profit Margin	-287.06%	-149.27%	-152.50%	-253.45%	-8823.87%
Free Cash Flow Margin	-299.05%	-214.53%	-226.17%	91.55%	8787.65%
EBITDA	-86.79	-83.49	-74.29	-42.91	-23.56
EBITDA Margin	-280.76%	-159.66%	-165.98%	-249.46%	-
D&A For EBITDA	5.48	5.41	4.21	1.73	0.39
EBIT	-92.27	-88.9	-78.49	-44.64	-23.95
EBIT Margin	-298.48%	-170.00%	-175.38%	-259.53%	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q